Quotient Sciences and CPI, a UK manufacturing entity, have agreed to form a joint venture aimed at accelerating the development of RNA-based therapies. The partnership, announced on 2 September, will combine Quotient’s Translational Pharmaceutics platform with CPI’s expertise in RNA manufacture and lipid nanoparticle (LNP) encapsulation, creating what the partners describe as the first fully integrated offering for mRNA drug product development.
